RT Journal Article
T1 Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
A1 Rodriguez-Arboli, Eduardo
A1 Martinez-Cuadron, David
A1 Rodriguez-Veiga, Rebeca
A1 Carrillo-Cruz, Estrella
A1 Gil-Cortes, Cristina
A1 Serrano-Lopez, Josefina
A1 Bernal Del Castillo, Teresa
A1 Martinez-Sanchez, Maria Del Pilar
A1 Rodriguez-Medina, Carlos
A1 Vidriales, Belen
A1 Bergua, Juan Miguel
A1 Benavente, Celina
A1 Garcia-Boyero, Raimundo
A1 Herrera-Puente, Pilar
A1 Algarra, Lorenzo
A1 Sayas-Lloris, Maria Jose
A1 Fernandez, Rosa
A1 Labrador, Jorge
A1 Lavilla-Rubira, Esperanza
A1 Barrios-Garcia, Manuel
A1 Tormo, Mar
A1 Serrano-Maestro, Alfons
A1 Sossa-Melo, Claudia Lucia
A1 Garcia-Belmonte, Daniel
A1 Vives, Susana
A1 Rodriguez-Gutierrez, Juan Ignacio
A1 Albo-Lopez, Carmen
A1 Garrastazul-Sanchez, Maria Paz
A1 Colorado-Araujo, Mercedes
A1 Mariz, Jose
A1 Sanz, Miguel Angel
A1 Perez-Simon, Jose Antonio
A1 Montesinos, Pau
K1 Acute myeloid leukemia
K1 Allogeneic stem cell transplant
K1 Autologous stem cell transplant
AB Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P
PB Elsevier
YR 2020
FD 2020-12-24
LK http://hdl.handle.net/10668/17556
UL http://hdl.handle.net/10668/17556
LA en
NO Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C, Serrano-López J, et al. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. Transplant Cell Ther. 2021 Apr;27(4):311.e1-311.e10
NO Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233).
DS RISalud
RD Apr 11, 2025